LSM10 antibody

Catalog No. ABIN7246445

Product Details anti-LSM10 Antibody

Target: LSM10 (LSM10, U7 Small Nuclear RNA Associated (LSM10))

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This LSM10 antibody is un-conjugated

Application: ELISA, Immunohistochemistry (IHC)

Characteristics: Polyclonal Antibody

Purification: Antigen affinity purification

Immunogen: Fusion protein of human LSM10

Isotype: IgG

Application Details

Application Notes: IHC 1:50-1:300, ELISA 1:5000-1:10000

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.9 mg/mL

Buffer: PBS with 0.05 % Sodium azide and 40 % Glycerol, pH 7.4

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Avoid freeze / thaw cycles.

Target Details for LSM10

Target: LSM10 (LSM10, U7 Small Nuclear RNA Associated (LSM10))

Alternative Name: LSM10 (LSM10 Products)

Synonyms: MST074 antibody, MSTP074 antibody, LSM10, U7 small nuclear RNA associated antibody, U7 snRNP-specific Sm-like protein LSM10 antibody, LSM10 antibody, lsm10 antibody, Lsm10 antibody

Background: LSm10 (U7 snRNA-associated Sm-like protein LSm10) is a nuclear protein that belongs to the snRNP (small nuclear ribonucleoproteins) Sm protein family. The survival of motor neurons (SMN) complex mediates the assembly of snRNPs involved in splicing and histone RNA processing. A crucial step in this process is the binding of Sm proteins onto the SMN protein. LSm10 and LSm11, mammalian homologs of the yeast Sm proteins D1 and D2, are important for U7 snRNP function and subcellular localization. U7 snRNP is an RNA molecule involved in the splicing of animal histone pre-mRNAs. Lsm10 and Lsm11 also associate with pICln (Chloride ion current inducer protein), which interacts with Sm proteins to inhibit their assembly on U RNA. LSm10 interactions with U7 snRNA and pICln may provide the means for using modified U7 snRNA derivatives to alter specific pre-mRNA splicing events, potentially leading to advances in antisense gene therapy.

UniProt: Q969L4